Related Experiment Video
Updated: Dec 2, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
3.1K
Antidiabetes Agents against Sars-Cov-2 Infection
Antonio Vitiello1, Francesco Ferrara1
1Pharmaceutical Department, Usl Umbria 1, A.Migliorati street, 06132 Perugia, Italy.
SN Comprehensive Clinical Medicine
|November 2, 2020
Summary
People with diabetes face severe COVID-19 risks. Some diabetes medications may offer benefits beyond blood sugar control against SARS-CoV-2 infection, warranting further investigation.
Area of Science:
- Endocrinology
- Infectious Diseases
- Pharmacology
Background:
- Chronic diseases, particularly diabetes, increase the risk of severe complications from SARS-CoV-2 (COVID-19).
- Diabetic patients exhibit a higher susceptibility to severe outcomes, including acute respiratory distress and multi-organ dysfunction, due to COVID-19.
- Effective management of both glycemic control and infection is crucial for mitigating risks in diabetic populations.
Purpose of the Study:
- To review the potential of antidiabetic agents as therapeutic options against SARS-CoV-2 infection.
- To explore evidence suggesting efficacy of certain antidiabetic drugs beyond their glucose-lowering effects.
Main Methods:
- Literature review of existing studies on antidiabetic agents and SARS-CoV-2.
- Analysis of research investigating the extra-glycemic effects of antidiabetic medications.
Main Results:
- Preliminary evidence suggests some antidiabetic drugs possess properties that may combat SARS-CoV-2.
- These agents might offer benefits independent of their primary role in diabetes management.
Conclusions:
- Antidiabetic agents represent a potential avenue for novel therapeutic strategies against COVID-19.
- Further research is warranted to elucidate the specific mechanisms and clinical utility of these drugs in treating SARS-CoV-2 infection.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
487
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
487
01:06Oral Hypoglycemic Agents: Glinides
449
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
449
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
426
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
426
01:24Glucagon-like Receptor Agonists
651
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
651
01:17Oral Hypoglycemic Agents: Sulfonylureas
586
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
586
01:23Dipeptidyl Peptidase 4 Inhibitors
417
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
417